On April 30, 2021, Ding Wei, deputy director of Huang Weijun of Fujian Provincial Food and Drug Administration, head of the Registration and Approval Office, Zhang Yong, director of the Drug Circulation Supervision Department, Huang Hairong, head of the Medical Device Supervision Office, and others came to our company to carry out research. The leaders in charge of the Municipal Market Supervision Bureau, the deputy director of Zhong Zhimin in Cangshan District, the deputy director of the Management Committee of Cangshan Functional Zone in the New District, the main leaders of the Free Trade Work Office and the District Industry and Information Technology Bureau of Cangshan Functional Zone in the New District, and the District Market Supervision Bureau and other leaders.
Chairman Kangxinshan warmly received the leaders on behalf of the company and thanked the provincial bureaus and departments at all levels for their strong support. At the symposium, Mr. Kang reported in detail to the research team on the research and development process and production and operation of the company's innovative drugs and generic drugs, and discussed with the participants on difficult needs such as registration approval, entrusted production management, talent introduction, innovative drug rewards and policy support.
Deputy Director Huang Weijun highly praised the company's achievements. As the first research and development enterprise in the history of Fujian Food and Drug Administration to issue a drug production license to MAH, Haixi New Pharmaceutical is a typical representative of Fujian drug research and development institutions. It is hoped that Haixi New Pharmaceutical will continue to increase scientific and technological innovation, enhance the soft power of enterprises, and improve the ability of industrial transformation. In his speech, he said that Fuzhou City and Cangshan District focus on cultivating and developing the biomedical industry. The purpose of this survey is to listen to and understand the opinions and suggestions of enterprises and all aspects, give full play to the joint action role of government and enterprises, and establish and develop international medicine.
